R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses the use of polygenic risk scoring to assess ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 ...

Reid Merryman, MD, discusses which patients are typically monitored for minimal residual disease and whether there are ...

ENGOT-cx11 is a randomized, double-blind, placebo-controlled trial that enrolled patients aged 18 years or older diagnosed ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ ...